Regeneron COVID-19 Cocktail’s Flame To Burn Brightly But Unclear For How Long
Antibody Products Will Be An Important Option Until Vaccines Reduce Infections
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
You may also be interested in...
The European Medicines Agency's special review process that was used to help EU member states issue emergency use approvals for dexamethasone in COVID-19 patients is now being applied to two antibody combinations from Regeneron/Roche and Lilly.
The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.
The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.